

References

I-211

1. Givlaari (givosiran), injection, for subcutaneous use [package insert]. Alnylam Pharmaceuticals, Inc. Cambridge, MA. 2019. Revised 11/2019.
2. Clinical Pharmacology™ 2021. Tampa FL: Gold Standard, Inc. Givosiran.
3. Micromedex DrugDex Compendium®. 2021. Givosiran.
4. Sardh E, Harper P, Balwani M, et al. Phase 1 Trial of an RNA interference therapy for acute intermittent porphyria. *N Engl J Med.* 2019; 380:549-558.
5. Gouya L, Sardh E, Balwani M, et al. ENVISION, A phase 3 study to evaluate the efficacy and safety of givosiran, an investigational RNAi therapeutic safety of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1, in acute hepatic porphyria patients. *Hepatology.* 70(1).e81-e82.
6. Balwani M, Sardh E, Ventura P, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. *N Engl J Med.* 2020;382(24):2289-2301.
7. Givosiran Sodium In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated January 13, 2020.